In a retrospective observational study conducted using a Japanese claims database, CDK4/6 inhibitors were found to be prescribed most commonly in combination with estrogen inhibitors (59%) in the context of HR+, HER2-negative advanced BC [25]. The gene discussed is CDK4; the disease is breast cancer.